☆ 4.6 Article

Explainable Machine Learning Model to Prediction EGFR Mutation in Lung Cancer

FRONTIERS IN ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Review Oncology

Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer

Jamie E. Chaft et al.

Summary: Biomarker-informed clinical trials are pushing the treatment of early-stage lung cancer beyond cytotoxic chemotherapy, with the incorporation of targeted and immunotherapies. Adjuvant osimertinib, preoperative chemoimmunotherapy, and adjuvant immunotherapy could improve outcomes for resectable lung cancer patients, and ongoing or planned studies focusing on biomarkers, immunotherapy, and targeted therapy may further enhance survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019

Jonathan M. Kocarnik et al.

Summary: The global burden of cancer is substantial and growing, with differences in burden based on Sociodemographic Index (SDI). The largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles from 2010 to 2019.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Medicine, General & Internal

Advances in systemic therapy for non-small cell lung cancer

Meagan Miller et al.

Summary: Lung cancer remains a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer being incurable for most patients. The optimal treatment for locally advanced NSCLC includes chemoradiation, while immunotherapy can be added for unresectable cases post-chemoradiation. Advances in targeted therapies and immunotherapy have transformed the landscape of NSCLC treatment.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Oncology

Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer

Jamie E. Chaft et al.

Summary: The treatment goal for early-stage lung cancer patients is cure, with surgical resection or radiotherapy as definitive local treatments along with adjuvant therapy to improve the likelihood of cure. New therapies lag behind due to inefficient trial designs and lengthy follow-ups, despite efforts to study surrogate endpoints to shorten trial durations.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates

Catherine B. Meador et al.

Summary: EGFR ins20 mutations, occurring in approximately 10% of EGFR-activating mutations, have historically shown reduced sensitivity to early-generation EGFR TKIs. However, recent advancements in scientific understanding and clinical detection techniques have improved our ability to develop effective therapies for this subset of EGFR-mutant NSCLC.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020

Haibo Qiu et al.

Summary: Cancer is a major cause of death and economic burden in China, with lower incidence but higher mortality and DALY rates compared to the US and UK. The cancer spectrum in China is changing, with increasing burden of certain cancers and a shift towards patterns seen in developed countries.

CANCER COMMUNICATIONS (2021)

Add to Collection

Review Oncology

Antitumour immunity regulated by aberrant ERBB family signalling

Shogo Kumagai et al.

Summary: Aberrant signalling of ERBB family members plays a key role in tumorigenesis and antitumour immunity evasion. While molecular-targeted agents and immunotherapies show efficacy in various cancers, their effectiveness is limited in cancers with activating gene alterations of ERBB family members.

NATURE REVIEWS CANCER (2021)

Add to Collection

Review Oncology

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

Peter T. Harrison et al.

SEMINARS IN CANCER BIOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

Narjust Duma et al.

MAYO CLINIC PROCEEDINGS (2019)

Add to Collection

Article Oncology

Cancer Progress and Priorities: Lung Cancer

Matthew B. Schabath et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)

Add to Collection

Article Respiratory System

Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning

Shuo Wang et al.

EUROPEAN RESPIRATORY JOURNAL (2019)

Add to Collection

Article Oncology

The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism

Jing Wang et al.

ANNALS OF TRANSLATIONAL MEDICINE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer

Jacqulyne P. Robichaux et al.

NATURE MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Higher Lung Cancer Incidence in Young Women Than Young Men in the United States

Ahmedin Jemal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Respiratory System

Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer

Feifei Dou et al.

RESPIRATORY RESEARCH (2018)

Add to Collection

Article Respiratory System

Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma

Elsa Davidsson et al.

MULTIDISCIPLINARY RESPIRATORY MEDICINE (2017)

Add to Collection

Article Oncology

Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study

Tomoya Kawaguchi et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Review Oncology

Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers

Aaron M. Chapman et al.

LUNG CANCER (2016)

Add to Collection

Article

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Yue-Lun Zhang et al.

Oncotarget (2016)

Add to Collection

Letter Respiratory System

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

Prasanta Raghab Mohapatra et al.

EUROPEAN RESPIRATORY JOURNAL (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.